enGene Posts 78% Expense Jump in Q3

enGene (NASDAQ:ENGN), a clinical-stage gene therapy company advancing treatments for bladder cancer, released its fiscal 2025 third-quarter earnings on Sept. 11, 2025. The period was highlighted by key clinical and regulatory milestones, including reaching the target enrollment for its pivotal LEGEND trial cohort, and receiving Regenerative Medicine Advanced Therapy (RMAT) status from the Food and Drug Administration (FDA) for its lead therapy, detalimogene (EG-70). Net losses more than doubled year over year, while operating expenses increased by approximately 78%, but the company reported a strong cash position expected to last into 2027. The absence of new clinical efficacy data and lack of explicit commercial guidance leave some open questions, but overall, the quarter brought notable progress at the clinical and regulatory levels.Source: enGene. Note: Fiscal 2025's third quarter ended July 31, 2025. Fiscal 2024's Q3 ended July 31, 2024.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool